Showing 19,861 - 19,880 results of 101,949 for search '(( 50 ms decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.68s Refine Results
  1. 19861
  2. 19862

    Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i><sub><i>k</i></sub> = 100,500,1000 (<i>kg</i>/<i>m</i><sup>2</sup> <i>s</i>) for outward protection (with nose clips) and inward protection model, respectively; the <i>k</i><sub><i>L</i></sub> for inward protection model is 0.5. by Akshay Anand (118579)

    Published 2025
    “…<p>Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i><sub><i>k</i></sub> = 100,500,1000 (<i>kg</i>/<i>m</i><sup>2</sup> <i>s</i>) for outward protection (with nose clips) and inward protection model, respectively; the <i>k</i><sub><i>L</i></sub> for inward protection model is 0.5.…”
  3. 19863

    Wnt Antagonist Secreted Frizzled-Related Protein 4 Upregulates Adipogenic Differentiation in Human Adipose Tissue-Derived Mesenchymal Stem Cells by Malini Visweswaran (696003)

    Published 2015
    “…Furthermore, there was significant 1.2-fold increase in peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer binding protein alpha (C/EBPα), and 1.3-fold increase in acetyl CoA carboxylase protein levels. In contrast, the expression of adipogenic proteins (PPARγ, C/EBPα, and acetyl CoA carboxylase) were decreased significantly with LiCl (by 1.6, 2.6, and 1.9-fold respectively) and BIO (by 7, 17, and 5.6-fold respectively) treatments. …”
  4. 19864

    Image3_Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia.jpeg by Heather A. Ogana (11774297)

    Published 2023
    “…<p>As effective therapies for relapse and refractory B-cell acute lymphoblastic leukemia (B-ALL) remain problematic, novel therapeutic strategies are needed. Artemis is a key endonuclease in V(D)J recombination and nonhomologous end joining (NHEJ) of DNA double-strand break (DSB) repair. …”
  5. 19865

    Image1_Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia.jpg by Heather A. Ogana (11774297)

    Published 2023
    “…<p>As effective therapies for relapse and refractory B-cell acute lymphoblastic leukemia (B-ALL) remain problematic, novel therapeutic strategies are needed. Artemis is a key endonuclease in V(D)J recombination and nonhomologous end joining (NHEJ) of DNA double-strand break (DSB) repair. …”
  6. 19866

    Image2_Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia.jpeg by Heather A. Ogana (11774297)

    Published 2023
    “…<p>As effective therapies for relapse and refractory B-cell acute lymphoblastic leukemia (B-ALL) remain problematic, novel therapeutic strategies are needed. Artemis is a key endonuclease in V(D)J recombination and nonhomologous end joining (NHEJ) of DNA double-strand break (DSB) repair. …”
  7. 19867
  8. 19868
  9. 19869
  10. 19870
  11. 19871
  12. 19872

    Association and dissociation of BODIPY FL GTPγS with PfG from <i>Plasmodium</i>. by Annette Kaiser (386455)

    Published 2015
    “…The increase in fluorescence was monitored until saturation over a time interval of 600 s. Part B At the arrow at t = 200 s, 20 μM unlabeled GTPγS was added and the decrease in fluorescence was monitored. …”
  13. 19873
  14. 19874
  15. 19875
  16. 19876
  17. 19877
  18. 19878
  19. 19879
  20. 19880